Katamaran Capital LLP Sells 7,654 Shares of Insulet Corporation $PODD

Katamaran Capital LLP lowered its holdings in Insulet Corporation (NASDAQ:PODD) by 66.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,881 shares of the medical instruments supplier’s stock after selling 7,654 shares during the period. Insulet makes up about 1.1% of Katamaran Capital LLP’s holdings, making the stock its 24th biggest position. Katamaran Capital LLP’s holdings in Insulet were worth $1,219,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Ramirez Asset Management Inc. grew its stake in Insulet by 50.0% during the second quarter. Ramirez Asset Management Inc. now owns 300 shares of the medical instruments supplier’s stock valued at $94,000 after acquiring an additional 100 shares in the last quarter. IFP Advisors Inc grew its stake in Insulet by 7.4% during the second quarter. IFP Advisors Inc now owns 1,358 shares of the medical instruments supplier’s stock valued at $472,000 after acquiring an additional 93 shares in the last quarter. Callan Family Office LLC purchased a new position in Insulet during the second quarter valued at approximately $375,000. US Bancorp DE grew its stake in Insulet by 3.7% during the second quarter. US Bancorp DE now owns 14,814 shares of the medical instruments supplier’s stock valued at $4,654,000 after acquiring an additional 533 shares in the last quarter. Finally, Maryland State Retirement & Pension System grew its stake in Insulet by 4.4% during the second quarter. Maryland State Retirement & Pension System now owns 3,408 shares of the medical instruments supplier’s stock valued at $1,071,000 after acquiring an additional 144 shares in the last quarter.

Analysts Set New Price Targets

PODD has been the subject of several recent analyst reports. Canaccord Genuity Group boosted their price objective on shares of Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a research note on Monday, September 29th. JPMorgan Chase & Co. boosted their price objective on shares of Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Morgan Stanley reaffirmed an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. Citigroup reissued a “buy” rating on shares of Insulet in a research note on Tuesday, July 8th. Finally, Piper Sandler boosted their price target on shares of Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $346.83.

Insiders Place Their Bets

In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by company insiders.

Insulet Price Performance

Shares of Insulet stock opened at $320.38 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet Corporation has a 52-week low of $226.50 and a 52-week high of $353.50. The company has a fifty day moving average of $323.15 and a 200-day moving average of $299.83. The stock has a market capitalization of $22.55 billion, a price-to-earnings ratio of 97.38, a price-to-earnings-growth ratio of 2.62 and a beta of 1.40.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million for the quarter, compared to analysts’ expectations of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm’s revenue was up 32.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.